Celladon Corporation is merged with Eiger BioPharmaceuticals.

Celladon Corporation and Eiger BioPharmaceuticals, Inc., a privately-held biopharmaceutical company, announced that they have entered into a definitive merger agreement under which the stockholders of Eiger would become the majority owners of Celladon, and the operations of Celladon and Eiger would be combined. The proposed merger remains subject to certain conditions, including the approval of Celladon stockholders. If approved, upon closing of the transaction, Celladon will be renamed Eiger BioPharmaceuticals, Inc. The directors and executive officers of Celladon will resign from their positions with Celladon upon the closing of the proposed merger, and the combined company will be under the leadership of Eiger�s current executive management team with David Cory serving as President and Chief Executive Officer.